Keywords: Biosimilars, Health care cost savings, Europe, Expenditures, Development costs, IGEES, Sandoz, Novartis
Biosimilars can save eight EU countries up to 33 billion euros on health care by 2020
Article | 16 May 2012
By 2020, eight countries in the European Union could save a cumulative total of between 11.8 billion euros ($15.2 billion) and 33.4 billion euros ($4.38 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
